Summit plunges 70 percent as muscle-wasting disorder drug fails

(Reuters) - Britain's Summit Therapeutics Plc said on Wednesday that it would stop developing its Duchenne muscular dystrophy (DMD) drug, ezutromid, after it failed a mid-stage study, sending its shares plunging more than 70 percent.


from Reuters: Health News https://ift.tt/2tz1hUs

No comments:

Post a Comment

Teen struggling w/ weight + no support at home, where the hell do I even start?

So I’m a teenager and I’ve been overweight/obese basically my whole life. And it’s been messing with me pretty bad. For the record, I don’...